Eli Lilly (LLY) Retatrutide Shows 28.3% Average Weight Loss in Phase 3 Trial
Covered by 1 source · 1 article
Eli Lilly's retatrutide delivered 28.3% average weight loss in a Phase 3 trial, lifting LLY almost 9% in August and supporting a $1.1T valuation.
Covered by